辽宁奥克化学股份有限公司 关于追加 2023 年度日常关联交易额度预计的公告 辽宁奥克化学股份有限公司 关于追加2023年度日常关联交易额度预计的公告 证券代码：300082 证券简称：奥克股份 公告编号：2023-041 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 辽宁奥克化学股份有限公司（以下简称"公司"）于 2023 年 4 月 17 日召 开第六届董事会第四次会议、第六届监事会第三次会议，审议通过了《关于确认 2022 年度日常关联交易和预计 2023 年度日常关联交易额度的议案》，并于 2023 年 5 月 19 日年度股东大会审批通过。具体内容请见公司于 2023 年 4 月 19 日 在巨潮资讯网披露的《关于确认 2022 年度日常关联交易和预计 2023 年度日常 关联交易额度的公告》。 基于公司业务发展及日常生产经营需要，公司于 2023 年 8 月 25 日召开第 六届董事会第七次会议、第六届监事会第五次会议，审议通过《关于追加 2023 年度公司日常关联交易额度预计的议案》，公司拟追加 20 ...

证券代码：300082 证券简称：奥克股份 公告编号：2023-045 辽宁奥克化学股份有限公司 关于会计政策变更的公告 辽宁奥克化学股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 辽宁奥克化学股份有限公司（以下简称"公司"）根据中华人民共和国财政部 （以下简称"财政部"）颁布的企业会计准则变更相应的会计政策，根据《深圳证 券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》等相关规定， 公司本次会计政策变更事项属于根据法律法规或者国家统一的会计制度要求的会 计政策变更，该事项无需提交公司董事会、股东大会审议。本次会计政策变更不涉 及对以前年度的追溯调整，不会对公司的损益、总资产、净资产等产生影响。现将 有关情况公告如下： 一、会计政策变更概述 1、会计政策变更原因及变更日期 2022年11月30日，财政部发布了《企业会计准则解释第16号》（财会〔2022〕 31号）（以下简称"16号准则解释"），规定"关于单项交易产生的资产和负债相 关的递延所得税不适用初始确认豁免的会计处理"的内容自2023年1月1日起施行； "关 ...

辽宁奥克化学股份有限司 第六届监事会第五次会议决议公告 证券代码：300082 证券简称：奥克股份 公告编号：2023-044 辽宁奥克化学股份有限公司 第六届监事会第五次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1 辽宁奥克化学股份有限公司（以下简称"公司"）第六届监事会第五次会议 通知于2023年8月15日以通讯、电子邮件发出，会议于2023年8月25日在江苏奥克 化学有限公司会议室以现场结合通讯表决的方式召开，本次会议应参加表决监事 5人，实际参加表决监事5人。会议由监事会主席仲崇纲先生主持，会议的召集、 召开和表决程序符合法律、法规及《公司章程》的规定。本次会议审议通过了以 下议案： 一、审议通过了《公司2023年半年度报告全文及摘要》； 监事会意见：经审核，监事会认为董事会编制和审核《公司2023年半年度报 告》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完 整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗漏。 具体内容请见公司于同日在巨潮资讯网（http//www.cninfo.com.cn）披露的 ...

辽宁奥克化学股份有限公司 关于聘任公司副总裁的公告 证券代码：300082 证券简称：奥克股份 公告编号：2023-040 1 辽宁奥克化学股份有限公司 关于聘任公司副总裁的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 辽宁奥克化学股份有限公司（以下简称"公司"）于2023年8月25日召开第 六届董事会第七次会议审议通过《关于聘任公司副总裁的议案》，同意聘任陈杨 英先生（简历详见附件）为公司副总裁。任期自本次董事会审议通过之日起至第 六届董事会届满之日止。 截至披露日，陈杨英先生直接持有公司股份300股。陈杨英先生与公司实际 控制人、控股股东、其他持有公司5%以上股份的股东以及公司董事、监事、高 级管理人员不存在关联关系。未发现陈杨英先生有《公司法》、《公司章程》等 规定的有关不得担任高级管理人员的情形。 公司独立董事对董事会聘任公司副总裁事项无异议，并出具了独立意见，具 体内容详见公司同日在巨潮资讯网(http://www.cninfo.com.cn/)披露的《独立董事 关于第六届董事会第七次会议相关事项的独立意见》。 特此公告。 辽宁奥克化学股份有限公司 ...

公司负责人： 主管会计工作的负责人： 会计机构负责人： 上市公司2023年1-6月非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位：辽宁奥克化学股份有限公司 | | | | | | | | | | 金额单位：人民币万元 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的 | 2023 年初占用资 | 年 月占用累 2023 1-6 | 2023 1-6 年 月占用资 | 2023 1-6 年 月偿还累 | 2023 1-6 年 月占用资 | 占用形成原 | 占用性质 | | | | 关联关系 | 会计科目 | 金余额 | 计发生金额（不 含 利 息） | 金的利息（如 有） | 计发生金额 | 金余额 | 因 | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其附属企业 | | | | | ...

公司本次补充追加对 2023 年度日常关联交易的预计是公司及子公司正常开 展经营管理需要，关联交易事项公平、公正，交易价格遵循公允、合理的定价原 则，不存在损害公司及股东特别是中小股东利益的情形。因此，我们同意将该议 案提交公司第六届董事会第七次会议审议。 辽宁奥克化学股份有限公司独立董事 熊焰韧 卜新平 杨向宏 二〇二三年八月二十五日 独立董事事前认可意见 辽宁奥克化学股份有限公司（以下简称"公司"）根据《深圳证券交易所创 业板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号—创业板上 市公司规范运作》和《公司章程》等有关规定，在召开公司第六届董事会第七次 会议前向独立董事提供了《关于追加 2023 年度公司日常关联交易额度预计的议 案》及相关材料，作为公司的独立董事，本着对公司和投资者负责的原则，对此 议案所涉及的事项向公司有关部门和人员进行了询证，并就《关于追加 2023 年 度公司日常关联交易额度预计的议案》发表事前认可意见如下： 辽宁奥克化学股份有限公司 ...

辽宁奥克化学股份有限公司 第六届董事会第七次会议决议公告 证券代码：300082 证券简称：奥克股份 公告编号：2023-043 辽宁奥克化学股份有限公司 第六届董事会第七次会议决议公告 具体内容请见公司于同日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《关于追加2023年度日常关联交易额度预计的公告》。 辽宁奥克化学股份有限公司 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 辽宁奥克化学股份有限公司（以下简称"公司"）第六届董事会第七次会 议通知于 2023 年 8 月 15 日以电话、电子邮件等形式发出，会议于 2023 年 8 月 25 日在江苏奥克化学有限公司会议室以现场结合通讯表决方式召开。本次会议 应参加董事 9 人，实际参加董事 9 人，公司监事、高级管理人员列席会议，会 议由董事长朱建民主持。会议的召集、召开和表决程序符合法律、法规及《公 司章程》的规定。经表决，本次会议审议通过以下议案： 一、审议通过了《公司 2023 年半年度报告全文及摘要》； 《公司 2023 年半年度报告》全文及《 ...

辽宁奥克化学股份有限公司 2023 年半年度计提资产减值准备的公告 证券代码：300082 证券简称：奥克股份 公告编号：2023-042 辽宁奥克化学股份有限公司 2023年半年度计提资产减值准备的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为公允反映辽宁奥克化学股份有限公司（以下简称"公司"）资产的价值， 根据企业会计准则的相关规定，公司对各项资产进行清查，对存在减值迹象的资 产进行减值测试。2023年8月25日，公司召开了第六届董事会第七次会议、第六 届监事会第五次会议，审议通过了《关于2023年半年度计提资产减值准备的议 案》，公司拟对2023年半年度合并报表范围内的有关资产计提减值损失，具体情 况如下： 一、2023年半年度计提资产减值准备情况概述 1、本期计提资产减值准备的原因 根据《企业会计准则》及公司会计政策的相关规定，本着谨慎性原则，对公 司及下属子公司2023年半年度各类资产进行了全面清查，对应收款项回收的可 能性，各类存货的可变现净值，固定资产、在建工程、无形资产、长期股权投资 及商誉的可变现性进行了充分的评估和分析。以2023年6月 ...

Financial Performance - The net profit attributable to shareholders of the company decreased by over 50% compared to the same period last year, with the net profit after deducting non-recurring gains and losses being negative[4]. - The company's operating revenue for 2022 was CNY 5,639,151,805.71, a decrease of 16.05% compared to CNY 6,717,428,323.07 in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 5,595,492.74, down 98.41% from CNY 352,237,905.21 in 2021[24]. - The cash flow from operating activities in 2022 was CNY 305,997,532.78, a decline of 38.41% from CNY 496,827,950.63 in 2021[24]. - The total assets at the end of 2022 were CNY 6,416,452,608.88, a decrease of 5.13% from CNY 6,763,326,789.61 at the end of 2021[24]. - The company reported a basic earnings per share of CNY 0.01 for 2022, down 98.08% from CNY 0.52 in 2021[24]. - The company experienced a significant decline in net profit after deducting non-recurring gains and losses, with a net loss of CNY 27,567,613.53 in 2022 compared to a profit of CNY 337,566,539.11 in 2021, marking a 108.17% decrease[24]. - The revenue from concrete additives was CNY 4,485,435,630.8, a decrease of 18.93% compared to the same period last year, with a gross margin of 2.03%[76]. - The revenue from other industries reached CNY 1,117,361,970, reflecting a slight decrease of 1.44% year-on-year, with a gross margin of 15.12%[76]. Dividend and Profit Distribution - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from the capital reserve for the year 2022[5]. - The company plans to retain all profits for 2022, with no cash dividends, stock bonuses, or capital reserve transfers, due to significant capital expenditure needs and ongoing industrial transformation[191]. - The total distributable profit for the reporting period was 227,387,669.16 CNY[190]. - As of December 31, 2022, the accumulated undistributed profits of the parent company amounted to CNY 227,387,669.16, while the consolidated undistributed profits totaled CNY 634,792,953.21[191]. Risk Management and Compliance - The company is facing risks related to regulatory policies, industry development, and product application areas, which are detailed in the management discussion and analysis section[4]. - The company has a comprehensive risk management strategy in place to address potential challenges in its future development[4]. - The company has established and improved its internal control and risk management systems to enhance risk control capabilities and ensure sustainable business development[193]. - The internal control self-assessment report indicated no significant defects in financial reporting or non-financial reporting[197]. - The company has committed to maintaining compliance with relevant laws and regulations, ensuring the independence of its operations from controlling shareholders[198]. Market and Industry Trends - The construction chemical industry faced challenges, with real estate development investment declining by 10.0% in 2022, impacting demand for the company's products[35]. - The company is focused on high-end technology industrialization, particularly in the production of epoxy derivatives and new energy materials[34]. - The market for polycarboxylic acid superplasticizers is expected to maintain stable growth, with the industry moving towards a healthier and more sustainable direction[36]. - The domestic pharmaceutical excipients market is projected to grow in line with the rapid increase in the pharmaceutical manufacturing industry's output, which has seen a compound annual growth rate of over 20% in the past decade[40]. - The market for non-ionic surfactants is expected to maintain stable growth, driven by the increasing demand for personal care and cleaning products[44]. Research and Development - The company is committed to research and development, allocating a significant portion of its budget to innovate and improve product quality in the chemical sector[106]. - The company has established partnerships with research institutions to enhance the development of green surfactants[52]. - The company completed significant advancements in various R&D projects, including the development of injection-grade PEG300 and narrow-distribution polyoxyethylene[86][88]. - The company aims to enhance its competitiveness in the polyethylene glycol and pharmaceutical fields through new product developments and market expansion strategies[86][88]. - The company is actively pursuing mergers and acquisitions to enhance its competitive edge in the chemical industry[106]. Production and Capacity - The production capacity utilization for high-performance polycarboxylate superplasticizers is at 63%, with a design capacity of 854,000 tons and ongoing projects to add 300,000 tons[52]. - The company has a total of 10,000 tons of medicinal polyethylene glycol with a capacity utilization rate of 113%[52]. - The company has a production capacity of 300,000 tons of epoxy ethane and 1.6 million tons of ethoxylation, with a nationwide sales service network covering over 80% of its customers[59]. - The company is expanding its production capabilities in Hainan and Wuhan, with ongoing projects to increase capacity for various products[52]. Strategic Initiatives - The company plans to enhance product innovation and focus on the development of new energy battery materials and electronic chemicals, aiming for a strong market position in these emerging products[122]. - The company aims to optimize its production capacity and strengthen strategic partnerships in the epoxy supply chain, with plans to expand its coastal and riverside ethoxylation capacity to one million tons[122]. - The company is committed to increasing R&D investment, particularly in the development of green low-carbon products derived from epoxy and carbon dioxide[123]. - The company plans to enhance its digital transformation and smart systems to improve management efficiency and reduce operational costs[123]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next three years[164]. Governance and Management - The company has established a governance structure consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and coordinated operations[138]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[139]. - The company maintains independence from its controlling shareholder in terms of business, assets, personnel, and finance, ensuring a complete and independent operational capability[143]. - The company has a total of 955 production personnel, 92 sales personnel, 203 technical personnel, 57 financial personnel, and 197 administrative personnel[185]. - The company has implemented a dynamic salary management mechanism to attract and retain talent, with a focus on performance-based compensation[186].

Financial Performance - The company's operating revenue for 2021 was ¥6,717,428,323.07, representing a 17.67% increase compared to ¥5,708,496,215.32 in 2020[21] - The net profit attributable to shareholders for 2021 was ¥352,237,905.21, a decrease of 12.54% from ¥402,726,079.80 in 2020[21] - The net cash flow from operating activities decreased by 20.23% to ¥496,827,950.63 in 2021 from ¥622,849,757.51 in 2020[21] - The total assets at the end of 2021 were ¥6,763,326,789.61, an increase of 24.48% from ¥5,433,135,137.77 at the end of 2020[21] - The net assets attributable to shareholders increased by 5.16% to ¥3,449,480,545.49 at the end of 2021 from ¥3,280,376,280.91 at the end of 2020[21] - The basic earnings per share for 2021 was ¥0.52, down 11.86% from ¥0.59 in 2020[21] - The diluted earnings per share also stood at ¥0.52, reflecting the same decrease of 11.86% from the previous year[21] - The weighted average return on equity decreased by 1.50 percentage points to 10.63% in 2021 from 12.13% in 2020[21] Revenue Breakdown - In 2021, the total operating revenue for the company was approximately CNY 6.99 billion, with quarterly revenues of CNY 1.38 billion, CNY 1.73 billion, CNY 1.87 billion, and CNY 1.73 billion respectively[23] - The net profit attributable to shareholders for the year was approximately CNY 352 million, with quarterly profits of CNY 51.12 million, CNY 32.35 million, CNY 109.88 million, and CNY 158.89 million respectively[23] - The concrete admixture industry generated ¥5,532,793,673.04, accounting for 82.36% of total revenue, with a year-on-year growth of 20.89%[66] - Polyether monomer sales amounted to ¥5,532,793,673.04, with a sales volume increase of 20.19% compared to the previous year[69] Market and Product Development - The company is investing in the production of lithium battery electrolyte solvents, utilizing proprietary technology that is "world-first and internationally leading" for carbon dioxide resource utilization[33] - The domestic market for new energy materials, particularly lithium batteries, saw a significant growth with a 157.5% increase in sales of new energy vehicles in 2021, reaching 3.52 million units[33] - The pharmaceutical excipients industry is entering a stable development phase, with the company positioned as a major supplier to over 400 formulation enterprises in China[34] - The company is expanding its market presence in the pharmaceutical excipients sector, developing high-end injectable and raw material grade products for international markets[34] - The company is focusing on the development of epoxy-derived new energy battery materials and enhancing carbon dioxide resource utilization as part of its strategic goals during the 14th Five-Year Plan[33] Strategic Partnerships and Collaborations - The company has established partnerships with Shenzhen Yanyi New Materials Co., Ltd. to promote collaboration in the lithium battery electrolyte solvent sector[33] - The company has established strategic partnerships with major players like Sinopec and PetroChina, ensuring stable raw material supply[55] - The company established a strategic partnership with the China Daily Chemical Research Institute, achieving industrial production of ethoxylated fatty alcohols, reaching a leading level domestically[61] Research and Development - The company is developing new products and technologies, including proprietary catalysts and synthesis methods, to improve product performance and cost efficiency[45] - The company is focusing on expanding its product range through R&D and industrialization of over 20 new product results, enhancing its technological capabilities[61] - The company aims to increase R&D investment and enhance the integration of production, education, and research to improve technological contribution rates and optimize product structure[118] Environmental and Safety Management - The company has established various environmental protection facilities, including wastewater collection pools and online monitoring systems, which are all operating normally[195] - The company maintains a commitment to environmental standards, with no significant pollution incidents reported during the year[197] - The company has implemented a rainwater and sewage diversion system across its subsidiaries to enhance environmental protection measures[195] - The company is facing safety and environmental risks due to the handling of hazardous chemicals like ethylene and ethylene oxide, and it is investing in safety and environmental management systems[124] Governance and Management - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[130] - The company has established a fair and transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management[131] - The company actively engages in investor relations management, providing multiple channels for investors to access information and communicate[132] - The company has a complete and independent asset structure, including land, buildings, machinery, trademarks, patents, and proprietary technologies[134] Future Outlook and Strategic Goals - The company aims to achieve high-quality development through a unique organizational structure that emphasizes customer-centricity and resource integration[50] - The company has set a long-term vision for 2035, aligning its development strategy with national planning and market trends[50] - The company is committed to becoming a leading manufacturer of green low-carbon fine chemicals and new materials, aligning with national carbon neutrality goals[120] - The company plans to enhance its market response capabilities and increase the contribution of high-margin products through differentiated marketing strategies[118]